Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Testosterone enanthate
Xyosted · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Participants | EXPERIMENTAL | XYOSTED Injection (Testosterone enanthate) 25 mg / 0.5 mL, 50 mg / 0.5 mL, 75 mg / 0.5 mL, 100 mg / 0.5 mL |
| Name | Type | Description |
|---|---|---|
| Testosterone enanthate | COMBINATION_PRODUCT | XYOSTED 25 mg / 0.5 mL; XYOSTED 50 mg / 0.5 mL; XYOSTED 75 mg / 0.5 mL; XYOSTED 100 mg / 0.5 mL |
Inclusion Criteria: 1. Diagnosed with a deficiency or absence of endogenous testosterone due to primary or secondary hypogonadism of a known etiology. Children with combined hormone deficiencies are permitted to enroll (but the child must already be receiving treatment for concomitant hormonal defi...
Xyosted is being studied for testosterone replacement in male adolescents with hypogonadism. The Phase 3 trial enrolls males aged 12 years and older in the United States. Xyosted is a small molecule therapy in the endocrine therapeutic area.
Xyosted is being developed by Halozyme Therapeutics, Inc., which trades under the ticker HALO. The company is running a Phase 3 study of the drug for testosterone replacement in male adolescents with hypogonadism.
Xyosted is in Phase 3 clinical development. The ongoing trial is a 52-week study with a 24-month long-term extension evaluating safety, pharmacokinetics, and efficacy for testosterone replacement in male adolescents with hypogonadism.
Xyosted is being evaluated in the Phase 3 trial NCT06689085, titled a 52-week study plus 24-month long-term extension of safety, PK, and efficacy of XYOSTED for testosterone replacement in male adolescents with hypogonadism. The trial is recruiting in the United States and plans to enroll 100 participants.
Yes, Xyosted is also known as testosterone enanthate. It is a small molecule therapy being studied for testosterone replacement in male adolescents with hypogonadism.